A New Way to Identify Patients likely to have Multiple Sclerosis
Diagnosing Multiple Sclerosis (MS) can be very difficult and time consuming,
sometimes taking months to years to receive a diagnosis.
Initially, physicians need to exclude other diseases that have similar symptoms. In addition, MRI examinations are not always clear and clinical symptoms are often inconclusive. These factors make diagnosing MS a complex and sometimes lengthy process, which can be very frustrating for individuals and physicians.
In order to help patients and physicians identify patients with a high probability of having MS, Glycominds has introduced the gMS® Dx test, a new blood test for MS biomarkers. This revolutionary test helps physicians identify which patients that have had a first neurological event and a positive MRI are likely to develop MS.
Clinical Summary
Numerous studies show the gMS®Dx test delivers consistent, reproducible and accurate results. The gM®DX test provides clinically valuable information clinicians can use to help make decisions about the likelihood of having Multiple Sclerosis, based on approximately 1,500 patients studied to date. The gMS®Dx test confirms your diagnosis opinions and gives patients more confidence in their decisions regarding treatment.
Why Use the gMS® DX test?
-
NEW - First blood based biomarker test validated for MS
-
POWERFUL - High positive predictive value for identifying patients likely to have MS after the first neurological event
-
The gMS®Dx test differentiates MS from other neurological diseases
-
SIMPLE - Easy, non-invasive test, that complements MRI
gMS® is a registered trade mark of Glycominds Ltd. |
